Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the survival, disease response, and side effects of
Tasigna® (nilotinib) in patients who have malignant gliomas and are positive for Platelet
Derived Growth Factor Receptor (PDGFR) amplification. This study is designed to test the
hypothesis that patients with malignant gliomas with PDGFR amplification are sensitive to
PDGFR kinase inhibitors.